Generic Aadhaar, a start-up, plans to launch generic medicines of thyroid, hypertension, diabetes, antifungal, gastroenterology, lipidemic and pain management which will be available at minimum 50 per cent price of already existing branded medicines in the market.
The company will be launching 20 generic drugs in the above mentioned therapeutic areas which at all its Generic Aadhaar stores across the country from October 25.
Arjun Deshpande, Founder and CEO, Generic Aadhaar, said, ‘It feels motivating to keep the promise of reaching 100 cities, from Maharashtra to across India, in just four months. Launching our own 20 Generic Aadhaar products also gives immense happiness. Although now the list contains only 20 generic medicines, there are many more drugs which will be added to the list in the coming years.”
Besides this launch, the company also has nearly 30 more products in the pipeline for existing as well as other therapeutic areas. And it expects that their future launches of around 30 generic medicines will be available at the reduced price up to 72 per cent.
Also read: NIPER introduce M.Tech. programme in Medical Devices
To ensure the availability of quality medicines at lower price than branded medicines, it has also tied up with other pharma companies’ manufacturing facilities for different therapeutic categories.
“Generic Aadhaar directly deals with the manufacturer to our central warehouses and from there we distribute to city warehouses, which are located in 100 cities to deal with our franchise outlets and we don’t follow the traditional pharma supply chain business, which leads us to be an innovative rapidly growing start-up pharma company for the betterment of the common man of India,” added Deshpande.
Presently, the company has its presence in nearly 100 cities and going forward it aims to further expand its presence organically in the existing as well as in new cities.
The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.
